Premium
Colonic spreading of a non‐chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis
Author(s) -
WILDING I. R.,
KENYON C. J.,
CHAUHAN S.,
HOOPER G.,
MARSHALL S.,
McCRACKEN J. S.,
STAAB H. J.,
ARMBRECHT J.
Publication year - 1995
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1995.tb00365.x
Subject(s) - mesalazine , ulcerative colitis , enema , medicine , descending colon , gastroenterology , colitis , rectal administration , rectum , disease
SUMMARY Background : Rectal foam enemas provide for drug delivery to the distal colon for treatment of left sided ulcerative colitis. However, currently available formulations contain chlorofluorocarbons which are due to be phased out in the near future. The objective of this study was therefore to determine the degree of dispersion of a newly developed nonchlorofluorocarbon rectal foam preparation in ulcerative colitis patients. Methods : This was an open label non‐controlled study of a single administration of a mesalazine foam enema (two actuations containing 2 g of mesalazine in approximately 120 mL foam) in 10 patients with quiescent ulcerative colitis. Spreading of the 99m Tc‐labelled foam enema was assessed over a 4‐h period by the non‐invasive technique of gamma scintigraphy. Results : All patients retained the enema for the full 4‐h imaging period. In nine out of the 10 patients, the enema was observed to spread as far as the descending colon and on average 23% of the dose was present in the descending colon at 4 h post‐dose. Conclusions : The extent of spreading observed in the study supports the use of the formulation in the treatment of left sided ulcerative colitis.